Opus Genetics Secures Up to $155M via Senior Secured Notes and $5M Equity Investment

On April 2, 2026, Opus Genetics, Inc. entered into a senior secured note purchase agreement to issue up to $155 million in senior secured notes to OPCM SA LLC and other purchasers. The agreement includes a committed $105 million and an uncommitted $50 million. An initial $35 million tranche is expected to close on April 20, 2026. Subsequent tranches are milestone-dependent, including a $25 million tranche tied to the FDA Application Acceptance Date for OPGx-LCA5 and a $10 million tranche linked to its FDA Approval Date, both required by March 31, 2028. The notes mature on April 2, 2033, and feature a conversion option allowing purchasers to convert up to 10% of the principal into common stock at $6.72 per share within 18 months. Additionally, the company entered into a stock purchase agreement for the issuance of 1,116,070 shares of common stock at $4.48 per share, totaling approximately $5 million. Proceeds are intended for general corporate purposes and advancing the clinical pipeline.